Phase 2 study results of murlentamab, a monoclonal antibody targeting the Anti-Müllerian-Hormone-Receptor II (AMHRII), acting through Tumor Associated Macrophage (TAM) engagement in advanced/metastatic colorectal cancers 8 July 2019 Scientific publications C201 – WCGIC 2019 Gamamabs poster #LBA-004 abstract 214_20190701